Armistice Capital’s Larimar Therapeutics LRMR Stock Holding History

Armistice Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-181,500	Closed	-$2.59M	–	76
2019 Q2	$2.59M	Buy	181,500 +5,833	+3%	+$155K	0.16%	54
2019 Q1	$5.78M	Buy	175,667 +70,834	+68%	+$3.63M	0.32%	53
2018 Q4	$6.23M	Buy	104,833 +7,833	+8%	+$773K	0.47%	44
2018 Q3	$13.6M	Sell	97,000 -28,000	-22%	-$3.4M	0.82%	36
2018 Q2	$15.3M	Buy	125,000 +50,000	+67%	+$4.25M	1%	33
2018 Q1	$6.71M	Sell	75,000 -3,000	-4%	-$254K	0.51%	49
2017 Q4	$4.32M	Buy	78,000 +46,333	+146%	+$2.09M	0.43%	52
2017 Q3	$1.34M	Buy	+31,667	New	+$1.32M	0.16%	60
2017 Q2	–	Sell	-9,333	Closed	-$522K	–	63
2017 Q1	$522K	Buy	+9,333	New	+$463K	0.11%	47

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital's LRMR Position: Q3 2019 in Review

Armistice Capital sold out of Larimar Therapeutics (LRMR) in Q3 2019, closing a stake of 181,500 shares — an estimated $2.59M sold.

Armistice Capital first reported a position in LRMR in Q1 2017 and held it in 9 quarters. The position peaked at $15.3M in Q2 2018. 51 funds tracked by Wall St. Rank hold LRMR as of Q3 2019.

Armistice Capital reported no remaining Larimar Therapeutics position as of Q3 2019 after selling out during the quarter.
Armistice Capital sold 181,500 Larimar Therapeutics shares in Q3 2019, an estimated $2.59M.
Armistice Capital first reported a position in Larimar Therapeutics in Q1 2017 and held it in 9 quarters.
Armistice Capital's Larimar Therapeutics position peaked at $15.3M in Q2 2018.
51 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2019.

Based on Armistice Capital's 13F filing for Q3 2019, filed 14 Nov 2019.